Press Releases Incyte Corporation

Equities

INCY

US45337C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
53.09 ^USD	+0.28%		+2.61%	-15.45%

May. 01	TD Cowen Adjusts Price Target on Incyte to $80 From $88	MT
May. 01	RBC Capital Adjusts Price Target on Incyte to $60 From $65	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Incyte to Present at Upcoming Investor Conference	May. 02	BU
Incyte: Q1 Earnings Snapshot	Apr. 30	AQ
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs	Apr. 30	BU
'Shadow Trading' Verdict A Reminder For Companies To Review Insider Trading Policies And Train Insiders	Apr. 29	AQ
SEC Secures Groundbreaking Win In Shadow Trading Insider Trading Case	Apr. 27	AQ
"Shadow Trading" Is Insider Trading: Jury Establishes Liability In Historic Shadow Trading Case	Apr. 24	AQ
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists	Apr. 23	BU
SEC Wins Novel 'Shadow Trading' Trial Against Biopharma Executive	Apr. 22	AQ
Incyte to Report First Quarter Financial Results	Apr. 11	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - March 29, 2024	Apr. 01	AQ
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 29	BU
SEC v Panuwat: The SEC's Novel "Shadow Trading" Insider Trading Case Goes To Trial	Mar. 19	AQ
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis	Mar. 10	BU
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa	Mar. 10	BU
New Data from Incyte's Growing Dermatology Portfolio to Be Presented At the 2024 American Academy Of Dermatology Annual Meeting	Mar. 05	AQ
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting	Mar. 04	BU
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI	Feb. 29	BU
Knight Therapeutics Announces Launch of Minjuvi® in Brazil	Feb. 29	AQ
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease	Feb. 27	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am EDT